Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression

Psychotherapy and Psychosomatics

Volumn 86, Issue 3, 2017, Pages 162-167

  Wilkinson, Samuel T ^a,b   Wright, DaShaun ^a   Fasula, Madonna K ^a,b   Fenton, Lisa ^c   Griepp, Matthew ^a,b   Ostroff, Robert B ^a   Sanacora, Gerard ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Cognition; Cognitive behavior therapy; Ketamine; Major depressive disorder; Relapse; Treatment resistant depression

Indexed keywords

KETAMINE; ANTIDEPRESSANT AGENT;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE BEHAVIORAL THERAPY; DEMOGRAPHY; FEMALE; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; COGNITIVE THERAPY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAJOR DEPRESSION; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PROCEDURES; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTIDEPRESSIVE AGENTS; COGNITION; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019631072     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000457960     Document Type: Article

References (34)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
2. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ: Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134-1142.
3. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
4. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr: A randomized add-on trial of an Nmethyl-D-aspartate antagonist in treatmentresistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802.
5. Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L: A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 2016; 173: 816-826.
6. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV: Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74: 250-256.
7. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ: Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67: 139-145.
8. Liao Y, Tang J, Corlett PR, Wang X, Yang M, Chen H, Liu T, Chen X, Hao W, Fletcher PC: Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry 2011; 69: 42-48.
9. Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, Small SA: Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013; 78: 81-93.
10. Featherstone RE, Liang Y, Saunders JA, Tatard-Leitman VM, Ehrlichman RS, Siegel SJ: Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiol Dis 2012; 47: 338-346.
11. Morgan CJ, Muetzelfeldt L, Curran HV: Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 2009; 104: 77-87.
12. Papp M, Gruca P, Lason-Tyburkiewicz M, Willner P: Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression. Behav Pharmacol 2016; 28: 1-8.
13. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
14. Nagy D, Stoiljkovic M, Menniti FS, Hajos M: Differential effects of an NR2B NAM and ketamine on synaptic potentiation and gamma synchrony: relevance to rapid-onset antidepressant efficacy. Neuropsychopharmacology 2016; 41: 1486-1494.
15. Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, Zarate CA Jr: Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 2012; 72: 555-561.
16. Hollon SD, De Rubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R: Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005; 62: 417-422.
17. Hollon SD, Stewart MO, Strunk D: Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. Annu Rev Psychol 2006; 57: 285-315.
18. Strunk DR, De Rubeis RJ, Chiu AW, Alvarez J: Patients' competence in and performance of cognitive therapy skills: relation to the reduction of relapse risk following treatment for depression. J Consult Clin Psychol 2007; 75: 523-530.
19. Guidi J, Tomba E, Fava GA: The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry 2016; 173: 128-137.
20. Fenton L, Fasula M, Ostroff R, Sanacora G: Can cognitive behavioral therapy reduce relapse rates of depression after ECT? A preliminary study. J ECT 2006; 22: 196-198.
21. Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, Rothman DL, Mason GF, Sanacora G: Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychother Psychosom 2014; 83: 298-307.
22. Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, Mason GF: Cortical γ-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry 2006; 59: 284-286.
23. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
24. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDSSR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573-583.
25. Collie A, Maruff P, Darby DG, McStephen M: The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003; 9: 419-428.
26. Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO: Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 2014; 155: 123-129.
27. Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, Schak KM, Tye SJ, Ritter MJ, Frye MA, Bobo WV: Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord 2016; 206: 300-304.
28. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA Jr: Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012; 37: 1526-1533.
29. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS: Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010; 13: 71-82.
30. Fava GA, Guidi J, Rafanelli C, Sonino N: The clinical inadequacy of evidence-based medicine and the need for a conceptual framework based on clinical judgment. Psychother Psychosom 2015; 84: 1-3.
31. Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO: Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014; 17: 1805-1813.
32. Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV: Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology 2015; 40: 1084-1090.
33. Morgan CJ, Muetzelfeldt L, Curran HV: Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010; 105: 121-133.
34. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB: Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172: 950-966.